Literature DB >> 27233679

Multi drug resistance and Extended Spectrum Beta Lactamases in clinical isolates of Shigella: A study from New Delhi, India.

Prabhav Aggarwal1, Beena Uppal2, Roumi Ghosh2, S Krishna Prakash2, Anita Chakravarti2, Arun Kumar Jha2, Krishnan Rajeshwari3.   

Abstract

BACKGROUND: Shigella is an important cause of gastroenteritis in local Indian population, as well as of traveler's diarrhea in the international visitors to India. These patients often require appropriate antimicrobial therapy; however, rapid development of antimicrobial resistance poses a major hurdle in achieving this goal.
METHOD: A prospective study was conducted during 2009-12 in New Delhi, India, including 6339 stool samples from gastroenteritis patients. 121 Shigella strains were identified on the basis of colony morphology, biochemical reactions, serotyping and ipaH gene based PCR. Antimicrobial susceptibility testing by disc diffusion, MIC determination by Vitek(®) 2 and phenotypic tests for ESBL/AmpC production were done.
RESULTS: Nineteen percent strains (23/121) were found to be resistant to third generation cephalosporins and all were phenotypically confirmed to be ESBL producers; one strain was positive for AmpC. ESBL producing strains were also found to be significantly more resistant (p < 0.05) to several other antimicrobials agents in comparison to ESBL non-producers, [ampicillin (100% vs. 62.2%), ampicillin/sulbactam (100% vs. 30.6%), cotrimoxazole (100% vs. 77.6%), ciprofloxacin (87.0% vs. 49.0%), ofloxacin (87.0% vs. 52.0%) and gentamicin (30.4% vs. 7.1%)]. Multidrug resistance was seen in 76% strains.
CONCLUSIONS: Inappropriate use of antimicrobial agents puts high selection pressure on the higher-end antibiotics. Multi-drug resistance and high rates of ESBL production by Shigella is a matter of concern for the local population as well as international travelers. Therefore, better national level antimicrobial management programs are the priority needs.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimicrobial susceptibility testing; Diarrhea; Dysentery; Minimum inhibitory concentration

Mesh:

Substances:

Year:  2016        PMID: 27233679     DOI: 10.1016/j.tmaid.2016.05.006

Source DB:  PubMed          Journal:  Travel Med Infect Dis        ISSN: 1477-8939            Impact factor:   6.211


  7 in total

1.  High Burden of Antimicrobial Resistance and Mortality Among Adults and Children With Community-Onset Bacterial Infections in India.

Authors:  Vidya Mave; Ajay Chandanwale; Anju Kagal; Sandhya Khadse; Dileep Kadam; Renu Bharadwaj; Vaishali Dohe; Matthew L Robinson; Aarti Kinikar; Samir Joshi; Priyanka Raichur; Katie McIntire; Savita Kanade; Jonathan Sachs; Chhaya Valvi; Usha Balasubramanian; Vandana Kulkarni; Aaron M Milstone; Ivan Marbaniang; Jonathan Zenilman; Amita Gupta
Journal:  J Infect Dis       Date:  2017-04-15       Impact factor: 5.226

2.  Shigellosis Caused by CTX-M Type ESBL Producing Shigella flexneri in Two Siblings of Rural Nepal: First Case Report from the Country.

Authors:  Narayan Prasad Parajuli; Govardhan Joshi; Bashu Dev Pardhe; Jyotsna Shakya; Anjeela Bhetwal; Shreena Shakya; Roshan Pandit; Sumesh Shreekhanda Shrestha; Puspa Raj Khanal
Journal:  Case Rep Infect Dis       Date:  2017-02-21

Review 3.  Antimicrobial susceptibility profile & resistance mechanisms of Global Antimicrobial Resistance Surveillance System (GLASS) priority pathogens from India.

Authors:  Balaji Veeraraghavan; Kamini Walia
Journal:  Indian J Med Res       Date:  2019-02       Impact factor: 2.375

4.  Antimicrobial resistance, virulence & plasmid profiles among clinical isolates of Shigella serogroups.

Authors:  Dhiviya Prabaa Muthuirulandi Sethuvel; Susmitha Perumalla; Shalini Anandan; Joy Sarojini Michael; Naveen Kumar Devanga Ragupathi; Revathi Gajendran; Kamini Walia; Balaji Veeraraghavan
Journal:  Indian J Med Res       Date:  2019-02       Impact factor: 2.375

5.  The Mortality Burden of Multidrug-resistant Pathogens in India: A Retrospective, Observational Study.

Authors:  Sumanth Gandra; Katie K Tseng; Anita Arora; Bhaskar Bhowmik; Matthew L Robinson; Bishnu Panigrahi; Ramanan Laxminarayan; Eili Y Klein
Journal:  Clin Infect Dis       Date:  2019-08-01       Impact factor: 9.079

Review 6.  A Phage Therapy Guide for Clinicians and Basic Scientists: Background and Highlighting Applications for Developing Countries.

Authors:  Ali Khalid; Ruby C Y Lin; Jonathan R Iredell
Journal:  Front Microbiol       Date:  2021-02-11       Impact factor: 5.640

7.  Azithromycin Resistance in Shigella spp. in Southeast Asia.

Authors:  Thomas C Darton; Ha Thanh Tuyen; Hao Chung The; Paul N Newton; David A B Dance; Rattanaphone Phetsouvanh; Viengmon Davong; James I Campbell; Nguyen Van Minh Hoang; Guy E Thwaites; Christopher M Parry; Duy Pham Thanh; Stephen Baker
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.938

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.